Chemistry, Analysis, and Biological Aspects of Daprodustat, A New Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor: A Comprehensive Review

IF 3.3 3区医学 Q2 CHEMISTRY, MEDICINAL Mini reviews in medicinal chemistry Pub Date : 2024-04-30 DOI:10.2174/0113895575293447240424052516

Roshani Patil, Sanjay Sharma

{"title":"Chemistry, Analysis, and Biological Aspects of Daprodustat, A New Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor: A Comprehensive Review","authors":"Roshani Patil, Sanjay Sharma","doi":"10.2174/0113895575293447240424052516","DOIUrl":null,"url":null,"abstract":"Background: The National Health and Nutrition Examination Survey (NHANES) carried out a survey between 2007-10 and found that as compared to the general population, the prevalence of anemia in chronic kidney disease (CKD) patients was twice high. Daprodustat is an investigational novel drug for the treatment of renal anemia. Objective: The objective of this study is to provide a comprehensive review of chemistry, synthesis, pharmacology, pharmacokinetic, and bioanalytical methods for the analysis of Daprodustat. Methods: To improve understanding, a review was carried out by creating a database of relevant prior research from electronic sources such as ScienceDirect and PubMed. The methodology is shown in the flowchart of the literature selection process. Results: The drug was approved in 2020 for therapeutic purposes in Japan. It is a novel drug approved for the treatment of anemia in chronic kidney disease for oral administration. It is intended for adults who have undergone dialysis for a minimum of four months and are experiencing anemia as a result of chronic kidney disease. Conclusion: This review examines therapeutic, pharmacological, and analytical aspects related to the novel drug Daprodustat.","PeriodicalId":18548,"journal":{"name":"Mini reviews in medicinal chemistry","volume":"43 1","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mini reviews in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113895575293447240424052516","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The National Health and Nutrition Examination Survey (NHANES) carried out a survey between 2007-10 and found that as compared to the general population, the prevalence of anemia in chronic kidney disease (CKD) patients was twice high. Daprodustat is an investigational novel drug for the treatment of renal anemia. Objective: The objective of this study is to provide a comprehensive review of chemistry, synthesis, pharmacology, pharmacokinetic, and bioanalytical methods for the analysis of Daprodustat. Methods: To improve understanding, a review was carried out by creating a database of relevant prior research from electronic sources such as ScienceDirect and PubMed. The methodology is shown in the flowchart of the literature selection process. Results: The drug was approved in 2020 for therapeutic purposes in Japan. It is a novel drug approved for the treatment of anemia in chronic kidney disease for oral administration. It is intended for adults who have undergone dialysis for a minimum of four months and are experiencing anemia as a result of chronic kidney disease. Conclusion: This review examines therapeutic, pharmacological, and analytical aspects related to the novel drug Daprodustat.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

一种新的缺氧诱导因子脯氨酰羟化酶抑制剂--达泊司他（Daprodustat）的化学、分析和生物学方面：全面综述

背景：美国国家健康与营养调查（NHANES）在 2007-10 年间进行了一项调查，发现与普通人群相比，慢性肾脏病（CKD）患者的贫血患病率高出一倍。达泊司他（Daprodustat）是一种治疗肾性贫血的试验性新药。研究目的本研究旨在对达普渡他的化学、合成、药理学、药动学和生物分析方法进行全面综述。研究方法为了加深理解，我们从 ScienceDirect 和 PubMed 等电子资源中创建了一个相关先前研究的数据库，从而进行了综述。方法见文献选择流程图。结果：该药物于 2020 年在日本获批用于治疗目的。它是一种新型药物，获准用于治疗慢性肾病贫血，口服给药。该药物适用于接受至少四个月透析并因慢性肾病而出现贫血的成人。结论本综述探讨了与新型药物达普洛司他相关的治疗、药理和分析方面的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Mini reviews in medicinal chemistry 医学-医药化学

CiteScore

7.80

自引率

0.00%

发文量

231

审稿时长

6 months

期刊介绍： The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines. Mini-Reviews in Medicinal Chemistry covers all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies. Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.